Advancing the Discovery and Development of New Antibiotics through Drug Repurposing
Deadline for manuscript submissions: 31 March 2024 | Viewed by 1602
Antimicrobial resistance (AMR) has now evolved in every class of antibiotics that have ever entered clinical use. The situation is worsened by the shrinking rate of return on the discovery of novel antibiotics. Current commercial antibiotics have two different origins: (1) natural products excreted by soil-dwelling Streptomyces, and (2) synthetic organic compounds. After eight decades of intensive screening and development, soil samples have failed to yield new classes of antibiotics since the end of the so-called golden era of antibiotic discovery. Although synthetic organic compounds have provided some important complementary classes of antibiotics, as represented by the advent of fluoroquinolones (e.g., ciprofloxacin), newer members from the family of synthetic antibiotics often share the known antimicrobial targets with the existing drugs in this class, making them susceptible to the development of the same type of resistance evolved in the previous members. In light of the high failure rates, considerable costs, and particularly substantial time spans of drug discovery and development, repurposing existing non-antibiotic drugs to treat multidrug-resistant bacterial infections should constitute an attractive approach to mitigating the threat of AMR.
Prof. Dr. Songping Huang
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.